Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

December 31, 2007

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

NVA237

single-dose dry-powder inhaler (SDDPI)

DRUG

Placebo

single-dose dry-powder inhaler (SDDPI)

DRUG

Tiotropium

Handihaler inhaler

Trial Locations (3)

Novartis Investigator Site, Vilvoorde

Novartis Investigator Site, Rueil-Malmaison

Novartis Investigator site, Tokyo